From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Does Finasteride Prevent Prostate Cancer?

Men who received finasteride for 7 years had a lower overall incidence of prostate cancer but a higher incidence of high-grade tumors.

Finasteride (Proscar), which inhibits conversion of testosterone to the more potent androgen dihydrotestosterone, reduces symptoms of benign prostatic hyperplasia (BPH). Because androgens promote the development of prostate cancer, a multicenter trial was undertaken to determine whether finasteride prevents prostate cancer.

Researchers randomized more than 18,000 men (age, 55 or older) with normal digital examinations and prostate-specific antigen (PSA) levels of ≤3 ng/mL to receive either finasteride (5 mg daily) or placebo for 7 years. During the trial, prostate biopsies were recommended if digital exams became abnormal or if PSA levels exceeded 4.0 ng/mL (in the finasteride group, PSA values were adjusted to account for finasteride's PSA-lowering effect); biopsies also were recommended for all participants at the end of the study. About half the participants ultimately underwent biopsies.

Among men who underwent biopsies, prostate cancer was diagnosed in 18.4% of finasteride recipients and 24.4% of placebo recipients -- a significant difference. However, high-grade tumors (Gleason score, 7-10) were diagnosed more frequently in the finasteride group than in the placebo group (6.4% vs. 5.1% of participants). Compared with placebo recipients, finasteride recipients experienced fewer urinary symptoms (due to finasteride's effect on BPH) but more sexual dysfunction.

Comment: The results of this study are not straightforward: Finasteride was associated with a reduced incidence of prostate cancer but with a greater proportion of cases with high-grade histology. The authors and an editorialist discuss several possible reasons for this finding, none of which is proven. The editorialist concludes, "on balance, finasteride does not seem to be an attractive agent for the chemoprevention of prostate cancer."

— Allan S. Brett, MD

Published in Journal Watch General Medicine July 18, 2003

Citation(s):

Thompson IM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 Jul 17; 349:215-24.

Scardino PT. The prevention of prostate cancer -- The dilemma continues. N Engl J Med 2003 Jul 17; 349:297-9.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2003. Massachusetts Medical Society. All rights reserved.